Bone Therapeutics should maybe say yes. The failure of its joint cushioning project JTA-004 a fortnight ago wiped 36% off its share price and appears to have prompted a takeover offer from a fellow French cell therapy company, Hybrigenics, which Bone says it is considering.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,